Correlation of liver enzymes with serum ferritin levels in β-thalassemia major

Rameshwar L. Suman, Anuradha Sanadhya, Pradeep Meena, Suresh Goyal


Background: Liver is the earliest site of iron deposition in transfusion dependent β -thalassemia major and iron induced liver injury is the common cause of morbidity. Liver enzymes are raised and indicative of liver injury in transfusion dependant β-thalassemia major patients. Objective of the study was to find out the correlation of serum ferritin with liver enzymes serum glutamic oxalocetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) in thalassemia major children.

Methods: Hospital based study of fifty five (55)  children of β-Thalassemia major in the age group of 4-20 years who were regularly transfused and were on oral iron chelators since at least one year were enrolled. Serum ferritin levels and serum SGOT and SGPT levels were estimated and results were correlated.

Results: Out of total fifty five (55) children, most were in the age group of 4 to 8 years. Mean rate of blood transfusion in subjects was 157.01ml/kg/year and mean duration of chelation therapy was 2.34 years. Serum ferritin levels were increased in β-thalassemic children with average of 2130.33±859.85ng/ml.  The SGOT and SGPT were also raised significantly (p value <0.05) with mean of 71.37±24.16 IU/L and 62.3 5±25.75 IU/L respectively. The values of SGOT & SGPT becomes highly significant  (p value <0.001) when serum ferritin  becomes more than 2000 ng/ml. Onset of liver enzyme derangement starts at serum ferritin level of more than 1000 ng/ml We found positive correlation between serum ferritin and deranged liver enzymes (Pearson’s bivariate correlation coefficient r = 0.84±84).

Conclusions: As soon as the serum ferritin level crosses the value of 1000 ng/ml and number of transfusions are more than 30, derangement in liver enzymes starts occurring in β -thalassemia major.



Hemolytic anemia, Liver enzymes, Serum ferritin, β-Thalassemia

Full Text:



Michel RD, Melissa JF, Elliott. Thalassemia syndrome. In kleigman RM, Stanton BF, St Geme JW, Behrman RE (editors) Nelson‘s textbook of paediatrics. 20th edition. Elsevier publication; 2015:2349-53.

Richa J, Sachdeva A. Iron overload and its manifestations. In: sachdeva A, Jain R, Aggarwal RK, Yadav SP, Broker A, eds. Manual of Thalassemia IAP. Pediatric hemato oncology chapter of IAP. 2009:76-115.

Hillenbra CM, Loeffler RB, Carville M. Mc. Evaluation of hepatic iron concentrations by T2 magnetic resonance imaging in patients with iron overload: comparison of T2 measurements at 1.5T and 3T and validation with liver biopsies. Proc Intl Soc Mag Reson Med. 2005;105:855-61.

Livrea MA, Tesoriere L, Pintaudi AM. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood .1996; 88(9):3608-14.

Kassab CA, Laradi S. Oxidant antioxidant status and metabolic data in patients with beta-thalassemia. Pediatr Blood Cancer. 2003;338.

Ameli M, Besharati S, Nemati K, Zamani F. Relationship between elevated liver enzymes with iron overload and viral hepatitis in thalassemia major patients in northern Iran. Saudi Med J. 2008;29(11):1611-15.

Sedigheh S, Mohammed TA, Maryam MM, Leili K, Heshmat I, Fahimah J et al. Evaluation of serum insulin, glucose, lipid profile and liver functions in beta-thalassemia major patients and their correlation with iron overload. Labmedicine. 2010;41:486-9.

Asharaf S, Mohammad Y, Fauzia al Y, Lolwa al N, Noora al M, Aml S, Vincenzo de S. Longitudinal study on liver functions in patients with thalassemia major before and after desferroxamine therapy. Mediterranian journal of hematology and infectious diseases. 2014;6.

Barton JC. Chelation therapy for iron overload Curr Gastroenterology. 2007;23:74-82.